ArQule +48.3% AH, DMC recommends continuation of Phase III METIV-HCC trial

|By:, SA News Editor

The DMC of ArQule's (ARQL) Phase III METIV-HCC trial in hepatocellular carcinoma recommends the continuation of the trial following a review of the data.

The data analyses among patients treated with 120 mg BID tivantinib tablets showed a reduced incidence of neutropenia.

Analyses also demonstrated that plasma exposure of the lower dose was comparable to that achieved with the 240 mg capsules employed in the Phase II trial.

ARQL +48.3% AH